E10-E14 – Diabetes mellitus: G-BA benefit assessments

38Decisions

125Patient groups

Added benefit by patient group

Considerable4
Minor14
Not proven107

Diseases in this disease block

E10 Diabetes mellitus, Typ 1 3 decisions
E11 Diabetes mellitus, Typ 2 36 decisions
E12 Diabetes mellitus in Verbindung mit Fehl- oder Mangelernährung [Malnutrition] 38 decisions
E13 Sonstiger näher bezeichneter Diabetes mellitus 33 decisions
E14 Nicht näher bezeichneter Diabetes mellitus 33 decisions

Decisions, newest first

Each decision lists only the patient groups coded with a disease in this disease block.

2026-08-20MounjaroTirzepatidNot proven
2025-02-20AwiqliInsulin icodecNot proven
2025-02-20AwiqliInsulin icodecNot proven: 4 of 4 patient groups
2024-06-20JardianceEmpagliflozinNot proven
2024-05-02MounjaroTirzepatidMinor: 1 of 8 patient groupsNot proven: 7 of 8 patient groups
2023-09-21TrulicityDulaglutidNot proven
2022-06-16ForxigaDapagliflozinNot proven: 2 of 2 patient groups
2022-05-19SteglatroErtugliflozinNot proven: 8 of 8 patient groups
2020-10-15SuliquaInsulin glargin/LixisenatidNot proven: 2 of 2 patient groups
2020-07-16TrulicityDulaglutidMinor: 2 of 5 patient groupsNot proven: 3 of 5 patient groups
2019-12-19ForxigaDapagliflozinMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
2019-12-19XigduoDapagliflozin/MetforminMinor: 3 of 6 patient groupsNot proven: 3 of 6 patient groups
2019-11-22GlyxambiEmpagliflozin/LinagliptinNot proven
2019-05-16TresibaInsulin degludecNot proven: 2 of 2 patient groups
2019-05-02OzempicSemaglutidMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
2019-03-22JanuviaSitagliptinMinor
2018-11-01SteglujanErtugliflozin/SitagliptinNot proven
2018-08-16SuliquaInsulin glargin/LixisenatidNot proven: 2 of 2 patient groups
2018-02-01KomboglyzeSaxagliptin/MetforminNot proven
2016-12-15JanumetSitagliptin/MetforminNot proven: 3 of 3 patient groups
2016-12-15JanuviaSitagliptinNot proven: 4 of 4 patient groups
2016-12-15KomboglyzeSaxagliptin/MetforminNot proven: 2 of 2 patient groups
2016-12-15OnglyzaSaxagliptinNot proven: 4 of 4 patient groups
2016-09-01SynjardyEmpagliflozin/MetforminNot proven: 6 of 6 patient groups
2016-09-01JardianceEmpagliflozinConsiderable: 4 of 10 patient groupsMinor: 1 of 10 patient groupsNot proven: 5 of 10 patient groups
2016-02-04XultophyInsulin degludec/LiraglutidNot proven
2015-10-15XultophyInsulin degludec/LiraglutidNot proven: 3 of 3 patient groups
2015-08-20TresibaInsulin degludecNot proven: 3 of 3 patient groups
2015-05-21GalvusVildagliptinNot proven
2015-02-05VokanametCanagliflozin/MetforminNot proven: 3 of 3 patient groups
2014-10-16TresibaInsulin degludecNot proven
2014-09-04InvokanaCanagliflozinNot proven: 5 of 5 patient groups
2013-10-01KomboglyzeSaxagliptin/MetforminNot proven
2013-10-01GalvusVildagliptinNot proven: 4 of 4 patient groups
2013-10-01EucreasVildagliptin/MetforminNot proven: 3 of 3 patient groups
2013-09-05Lyxumia LixisenatidNot proven: 4 of 4 patient groups
2013-05-16TrajentaLinagliptinNot proven
2013-02-21TrajentaLinagliptinNot proven: 3 of 3 patient groups

Data status: 2026-10-29